BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260303T150000
DTEND;TZID=Europe/Stockholm:20260303T160000
DTSTAMP:20260403T211440
CREATED:20260203T134458Z
LAST-MODIFIED:20260203T134500Z
UID:10001749-1772550000-1772553600@www.scilifelab.se
SUMMARY:PULSE Challenge: Brain delivery platform for large drug modalities
DESCRIPTION:Brain uptake of therapeutic modalities such as antibodies\, enzymes and other types of drug modalities is severely limited by their size due to the blood brain barrier (BBB). To address this issue\, we have developed the BrainTransporterTM (BT) technology to actively transport these molecules across the BBB using receptor-mediated transcytosis. Our technology is engineered using structural data as guidance to engage with a BBB receptor at an optimal site. \n\n\n\nHost: Per I ArvidssonModerator: Anna Ridderstad Wollberg \n\n\n\nThe seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE\, that will train 48 future leaders in life sciences. The program focuses on innovative\, fundamental and translational research carried out in supportive and diverse academic and industrial environments\, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE \n\n\n\n\n\n\n\nOn-line event via Zoom \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\nPresenter: Per-Ola Freskgård  \n\n\n\nBiography:Per-Ola Freskgård is currently Chief Scientific Officer at BioArctic AB and a member of the Research & Development Leadership Team. Per-Ola previously served as vice Director & Distinguished Scientist within the Roche Neuroscience Discovery organization in Switzerland responsible for preclinical development of the Brain Shuttle delivery technology of biologics\, which is now in clinical testing. Prior to that\, he held a Section Head position in early and late discovery at AstraZeneca within the Neuroscience area and a member of the Technology Research Review Committee within the Medimmune and AstraZeneca organizations. Before joining AstraZeneca\, Per-Ola served as Vice President and a member of the Executive Management Team at Nuevolution A/S and a co-inventor of the Chemetics technology. Prior to this\, Per-Ola was a Project Manager at Maxygen responsible for research programs of antibody mimetics and a co-inventor of the Maxybody concept. Prior to that\, Per-Ola was Head of the Discovery Research Department in the therapeutics division at Novo Nordisk A/S. Per-Ola conducted his post-doctoral fellowship in Professor Frances Arnold’s lab at the California Institute of Technology. He holds a Ph.D. in Protein Biochemistry from Linköping University\, Sweden. Authored and co-authored more than 80 per-reviewed publications and patent applications
URL:https://www.scilifelab.se/event/pulse-challenge-brain-delivery-platform-for-large-drug-modalities/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/02/Bild1-e1770905208628.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260224T150000
DTEND;TZID=Europe/Stockholm:20260224T160000
DTSTAMP:20260403T211440
CREATED:20260129T143238Z
LAST-MODIFIED:20260129T143240Z
UID:10001738-1771945200-1771948800@www.scilifelab.se
SUMMARY:PULSE Challenge: Catalysis - A guiding principle for biochemistry and professional career development
DESCRIPTION:This seminar will describe Dr. Lorenz M. Mayr‘s experience in drug discovery from over 30 years in industry\, academia\, venture capital/financing and finally running Biotech startup companies. He is driven by his passion for science\, interdisciplinary research and impact for patients. The ultimate goal has always been to bring innovative\, impactful and affordable medicine to patients. He has had success by working in Germany\, US\, UK\, Sweden and Switzerland\, but also made a number of mistakes. Quote: I am happy to share my experience and to help new entrepreneurs to pursue a career in drug discovery\, at academia or industry\, but ideally with novel startup companies.  \n\n\n\nHost: Kristian SandbergModerator: Anna Ridderstad \n\n\n\nThe seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE\, that will train 48 future leaders in life sciences. The program focuses on innovative\, fundamental and translational research carried out in supportive and diverse academic and industrial environments\, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE \n\n\n\n\n\n\n\nOn-line event via Zoom \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\nPresenter: Dr. Lorenz M. Mayr  \n\n\n\nBiography:Lorenz is working as Managing Director at BioMedTech Consulting GmbH in Basel\, Switzerland. The company provides consulting service to BioPharma\, Biotechnology and MedTech companies and academic institutions. He is also working as Chief Executive Officer (CEO) and Chairman of the Board (President) of PHiNE Bio AG\, a new Biotech startup company in Basel\, Switzerland which is operating since 08/2025 in stealth mode and financed by private investors. \n\n\n\nLorenz has long-lasting experience in Pharma/Biotech investments and company creation from his work at Syncona Ltd (London\, UK)\, Hevolution Foundation (Boston\, MA) and EIT-Health Gold Track (Boston\, MA; Munich\, Germany). Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery\, technology and innovation\, business growth and financing strategy. \n\n\n\nHe has previously worked as a Chairman\, Non-Executive Director\, Chief Executive Officer\, Chief Technology Officer\, and Entrepreneur-in-Residence in the Biotech\, Medtech\, Pharma and Venture Capital industry across Europe and the US. \n\n\n\nHe has received first class degrees in biochemistry\, biophysics\, molecular & cell biology at the University of Tubingen (Germany)\, University of Bayreuth (Germany) and the University of Colorado at Boulder (U.S.A.) and a number of fellowships & awards for his studies in Germany and the United States. \n\n\n\nLorenz currently serves on the Board of Directors at Fundamental Pharma (Heidelberg\, Germany)\, InCephalo (Basel\, Switzerland) and PHiNE Bio AG (Basel\, Switzerland)\, and serves on the Scientific Advisory Board of Fraunhofer IGB (Stuttgart\, Germany)\, Fraunhofer IZI (Leipzig\, Germany)\, SaxoCell (Leipzig)\, The Francis Crick Institute (London\, UK)\, Science4Life (Stockholm\, Sweden) SensibleBio (Oxford\, UK)\, Hemotune (Zurich\, Switzerland)\, Huidagene (Shanghai\, China)\, AstraGenomics (Shanghai\, China)\, TQ Therapeutics (Munich\, Germany)\, GeneFab (San Francisco\, CA) and NanoVation (Vancouver\, Canada)\, and works as Senior Healthcare Advisor to EQT Investments (Stockholm/Sweden).
URL:https://www.scilifelab.se/event/pulse-challenge-catalysis-a-guiding-principle-for-biochemistry-and-professional-career-development/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/02/Bild1-e1770905208628.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260212T150000
DTEND;TZID=Europe/Stockholm:20260212T160000
DTSTAMP:20260403T211440
CREATED:20260122T150648Z
LAST-MODIFIED:20260212T140707Z
UID:10001731-1770908400-1770912000@www.scilifelab.se
SUMMARY:PULSE Challenge: The Discovery of Seqitope and Opti-mAb Technologies
DESCRIPTION:The Seqitope® and Opti-Mab® technologies originated from projects together with SciLifeLab DDD.  Seqitope® is a high-resolution epitope mapping platform that combines large-scale wet-lab screening with advanced bioinformatics. By utilizing phage display of libraries containing millions of mutated antigen variants\, it goes far beyond classical alanine scanning. The platform uses next-generation sequencing to generate millions of reads per antibody\, providing exceptional resolution. While initially mapping 30 antibodies manually\, Seqitope® is now automation-compatible\, scaling to hundreds of antibodies simultaneously. Validated on targets like CD19 and IL8\, it generates data sets ideal for machine learning in antibody discovery. \n\n\n\nAdditionally\, we introduce Opti-mAb®\, engineered single-chain variable fragments (scFvs) designed to solve common issues like aggregation\, low expression\, and instability. These novel formats enhance therapeutic development for bispecific antibodies and cell-based therapies. Together\, Seqitope® and Opti-mAb® represent a significant leap in the scalability and precision of antibody engineering. \n\n\n\nHost: Kristian SandbergModerator: Anna Ridderstad Wollberg \n\n\n\nThe seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE\, that will train 48 future leaders in life sciences. The program focuses on innovative\, fundamental and translational research carried out in supportive and diverse academic and industrial environments\, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE \n\n\n\n\n\n\n\nOn-line event via Zoom \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\nPresenters: Dr. Daniel Johansson\, PhD and CSO at AAX Biotech \n\n\n\nBiography:Dr. Daniel Johansson\, Chief Scientific Officer at AAX Biotech\, where he has been actively involved for the past three years in developing novel antibody technologies. He earned his Ph.D. in molecular immunology from the Karolinska Institute\, with a focus on antibody discovery and engineering. With over 20 years of experience across academia and the biotech industry\, he co-founded AAX Biotech to translate solutions developed during a drug discovery and development (DDD) project into broadly applicable technologies. These efforts resulted in two proprietary platforms: Seqitope\, enabling high resolution\, high throughput epitope mapping\, and Opti-mAb\, facilitating high quality production of scFvs in CAR-T and bispecific antibodies—tools now positioned to support researchers and companies worldwide. \n\n\n\nDr. Mats AA Persson\, PhD\, KI and co-founder of AAX Biotech \n\n\n\nBiography:Dr Mats Persson has worked with molecular biology tools at Karolinska Institutet to generate\, characterize and engineer human monoclonal antibodies since a post doc period at Scripps Research Institute in La Jolla\, USA\, in the late 1980-ies. In particular\, he has been focusing on applying the techniques for studying anti-viral antibodies. This led him to co-found Molecules of Man AB in 2005\, a start-up devoted to commercialize antibodies to hepatitis C virus (HCV) for clinical use. However\, those antibodies were overtaken by highly efficient small molecule drugs (inhibiting the virus’s own enzymes)\, and thus did not reach the market. Undeterred\, he suggested a new infectious target for development of human antibodies at DDD. During this project\, technical hurdles were encountered that gave rise to novel solutions. And by now\, human monoclonal antibodies had revolutionized the pharma industry\, with biopharma being the real driver for hundreds if not thousands of novel drugs. Indeed\, it was not farfetched that solutions to problems shared by scores of biopharma projects could be worthwhile to explore commercially: AAX Biotech was born and incorporated for this purpose.
URL:https://www.scilifelab.se/event/pulse-challenge-the-discovery-of-seqitope-and-opti-mab-technologies/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/02/Bild1-e1770905208628.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260209T150000
DTEND;TZID=Europe/Stockholm:20260209T160000
DTSTAMP:20260403T211440
CREATED:20260123T120235Z
LAST-MODIFIED:20260126T114030Z
UID:10001733-1770649200-1770652800@www.scilifelab.se
SUMMARY:PULSE Challenge: From Serendipity to Design Principles Molecular Glues as a Prelude to RIPTACs
DESCRIPTION:Traditionally viewed as inhibitors\, small molecules have evolved through the discovery of molecular glues—compounds that create function by stabilizing protein-protein interactions. This shift from serendipitous discovery to “induced proximity” has expanded the druggable proteome and redefined how we control cellular behavior. \n\n\n\nThis talk traces the evolution of molecular glues\, framing them as versatile proximity-inducing agents rather than just degradation tools. I emphasize their impact on our understanding of protein surfaces and cellular organization. The second half introduces Regulated Induced Proximity Targeting Chimeras (RIPTACs). I highlight HLD-0915\, a novel RIPTAC targeting prostate cancer. In preclinical models\, HLD-0915 demonstrated tumor regression and a favorable therapeutic index\, even in drug-resistant cases. Finally\, I present Phase 1 data from mCRPC patients\, showing strong tolerability and encouraging anti-tumor activity in heavily pretreated populations. \n\n\n\nHost: Vasanthanathan PoongavanamModerator: Per Arvidsson \n\n\n\nThe seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE\, that will train 48 future leaders in life sciences. The program focuses on innovative\, fundamental and translational research carried out in supportive and diverse academic and industrial environments\, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE \n\n\n\n\n\n\n\nOn-line event via Zoom \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\nPresenter: Dr. Muthukumaran Venkatachalapathy  \n\n\n\nBiography:Dr. Muthukumaran Venkatachalapathy is currently an Associate Research Scientist in the Department of Chemistry at Yale University (with Professor Craig Crews and Prof David Spiegel). With a strong background in Chemical Biology\, he earned his Ph.D. from the Max Planck Institute in Dortmund\, Germany. His research interests focus on developing novel chemical biology modalities for targeted protein degradation and therapeutic discovery
URL:https://www.scilifelab.se/event/pulse-challenge-from-serendipity-to-design-principles-molecular-glues-as-a-prelude-to-riptacs/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/02/Bild1-e1770905208628.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251205T101500
DTEND;TZID=Europe/Stockholm:20251205T110000
DTSTAMP:20260403T211440
CREATED:20251120T134320Z
LAST-MODIFIED:20251120T140035Z
UID:10001671-1764929700-1764932400@www.scilifelab.se
SUMMARY:Discovery and developmentof GRK2-biased beta 2-adrenergic receptor agonists for the treatment of metabolic disorders
DESCRIPTION:Presenter: Dr Benjamin Pelcman\, Atrogi AB \n\n\n\nAtrogi AB is biotech company pioneering first-in-class treatments to revolutionize metabolic health. The talk will describe how targeting a novel GRK-biased b2-adrenergic receptor signaling pathway allows for the successful design of compounds useful in the treatment of disorders like type 2 diabetes (T2D)\, obesity and muscular wasting. The approach will be exemplified by the invention\, selection and development of ATR-258\, a b2-AR agonist that was developed for T2D and is about to enter phase 2 clinical trials. During the exploration of the chemical space\, a diverse set of molecules were synthesized\, and their effect on the downstream signaling will be discussed. In addition\, the seminar will illustrate differences between drug development in Big Pharma and small biotech and the challenges of working in an environment with limited resources. \n\n\n\nAfter receiving his Ph.D. in Organic Chemistry at KTH and a post doc session at Dartmouth College\, NH\, USA\, Benjamin joined Astra Pain Control\, first in Södertälje and then in Montreal\, as a medicinal chemist. Benjamin has also held various positions at Pharmacia & Upjohn\, Karo Bio\, Biolipox and Orexo. After having started his own consultancy company\, BeePCo\, he came in contact with Atrogi where he was employed first as a CEO and later as Head of Chemistry and IP. Benjamin is now retired but is still working as a consultant for Atrogi and other small biotechs.
URL:https://www.scilifelab.se/event/discovery-and-developmentof-grk2-biased-beta-2-adrenergic-receptor-agonists-for-the-treatment-of-metabolic-disorders/
LOCATION:BMC Room C4:301\, Husargatan 3\, entrance C1\, Uppsala\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251105T100000
DTEND;TZID=Europe/Stockholm:20251105T110000
DTSTAMP:20260403T211440
CREATED:20250922T082246Z
LAST-MODIFIED:20250923T075718Z
UID:10001619-1762336800-1762340400@www.scilifelab.se
SUMMARY:From repurposing anti-parasitic drug to prodrugs towards cancer and lupus treatments
DESCRIPTION:Welcome to this DDD exit seminar\, hosted by the DDD platform in Navet\, Uppsala.  \n\n\n\nPlease register below for either on site or online attendance. \n\n\n\nRegistration\n\n\n\nSpeakers\n\n\n\nPeter Nygren is a senior physician in oncology\, specializing in gastrointestinal cancer\, at Akademiska hospital and a professor of oncology at the Department of Immunology\, Genetics and Pathology\, Uppsala University since 2005. Peter’s research focuses on the development and validation of treatment predictive tests\, the development of new cancer drugs and the improvement of the treatment of gastrointestinal cancer\, including through dietary interventions. \n\n\n\nMårten Fryknäs is an Associate Professor and Senior Lecturer in Experimental Clinical Pharmacology at the Department of Medical Sciences\, Uppsala University. His research focuses on the development of cell-based assays\, drug screening\, and mechanism deconvolution in two- and three-dimensional models. The overall aim is to identify new approaches for the pharmacological treatment of cancer. \n\n\n\nRolf Larsson has been a professor and senior physician in clinical pharmacology at the Department of Medical Sciences\, Uppsala University since 2000. Rolf Larsson’s research focus is cancer pharmacology\, where the identification and development of new cancer drugs is a main focus. “Repurposing” of already existing drugs for use in cancer treatment is another area of ​​interest. \n\n\n\nAbstract\n\n\n\nScientific breakthroughs sometimes arise from unexpected observations. In our case\, it was a seemingly random discovery: that the established antiparasitic drug mebendazole also had significant effects against cancer and autoimmune disease. This observation became the starting point for a research program supported by SciLifeLab Drug Discovery and Development\, which we hope will open up new therapeutic strategies. \n\n\n\nHowever\, a key problem was the pharmacokinetic limitations of mebendazole\, which had long hampered the ability to exploit its full potential. To address this\, a prodrug was developed with the aim of improving the bioavailability and the pharmacodynamic profile. In parallel\, systematic work was carried out to clarify the molecular mechanism of action that had long eluded us and which required both methodological innovations and interdisciplinary approaches to solve.After several years of study\, we were finally able to identify a mechanism that explains the observed effects and thus sheds light on new biological links between mebendazole and key disease processes. The results not only provide a new understanding of how the substance works\, but also point to the possibility of developing a whole new class of therapeutics. \n\n\n\nAt our DDD-exit seminar\, we will present the scientific journey from random observation to mechanistic explanation and discuss the implications our findings may have for the future treatment of cancer and autoimmune diseases. \n\n\n\n\n\n\n\nHost: Ylva Gravenfors ylva.gravenfors@scilifelab.se and SciLifeLab Drug Discovery and Development Platform
URL:https://www.scilifelab.se/event/from-repurposing-to-prodrugs-from-parasite-towards-cancer-and-lupus-treatment/
LOCATION:Navet\, SciLifeLab Uppsala\, SciLifeLab Uppsala\, BMC C11\, Husargatan 3\, Uppsala\, 75237\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250317T130000
DTEND;TZID=Europe/Stockholm:20250317T140000
DTSTAMP:20260403T211440
CREATED:20250303T110411Z
LAST-MODIFIED:20250303T110412Z
UID:10001503-1742216400-1742220000@www.scilifelab.se
SUMMARY:PULSE Challenge: Selection and screening of antibody based drugs
DESCRIPTION:This presentation will provide an overview of the selection and screening processes\, as well as future challenges for antibody-based drugs. It will be exemplified with data from one of Alligator Bioscience’s bispecific antibody drug candidates\, ATOR-4066. ATOR-4066 is a novel bispecific antibody constructed in the RUBY™ format using Alligator Bioscience’s Neo-X-Prime platform. It targets the tumor-associated antigen CEA (CEACAM5) on tumor cells and CD40 on myeloid cells. ATOR-4066 is designed to induce efficient CEA-conditional activation of myeloid cells\, facilitate the uptake of neoantigen-containing tumor-derived material\, and subsequently drive the cross-priming of tumor-specific T cells\, resulting in long-lasting anti-tumor activity. \n\n\n\nThe seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE\, that will train 48 future leaders in life sciences. The program focuses on innovative\, fundamental and translational research carried out in supportive and diverse academic and industrial environments\, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE \n\n\n\n\n\n\n\nOn-line event via Zoom \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\nPresenter: Dr Peter Ellmark\, PhDChief Scientific OfficerAlligator bioscience\, Lund\, Sweden \n\n\n\nAbstract:Antibody-based drugs have revolutionized the treatment landscape for numerous serious conditions\, with a global market size exceeding $250 billion. The success of these drugs can be attributed to their high specificity and versatility. Critical to the successful development of antibody-based drugs is the appropriate selection and screening methodology\, which ensures that drug candidates meet all key criteria for successful development. \n\n\n\nA short speaker biography:Peter Ellmark joined Alligator Bioscience in 2008 and serves as Chief Scientist. He holds a PhD and an adjunct professorship in Immunotechnology at Lund University and has more than 20 years’ experience of developing antibodies for immunotherapy of cancer. Dr. Ellmark´s research interest is focused on developing mono- and bispecific antibodies\, in particular CD40 and 4-1BB targeting therapies\, for tumor directed immunotherapy of cancer.
URL:https://www.scilifelab.se/event/pulse-challenge-selection-and-screening-of-antibody-based-drugs/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/02/Bild1-e1770905208628.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250225T120000
DTEND;TZID=Europe/Stockholm:20250225T130000
DTSTAMP:20260403T211440
CREATED:20250206T095146Z
LAST-MODIFIED:20250210T141359Z
UID:10001477-1740484800-1740488400@www.scilifelab.se
SUMMARY:PULSE Challenge: ML/AI approaches for designing proximity-inducing small molecules  – PROTAC cell permeability and bioavailability
DESCRIPTION:The seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE\, that will train 48 future leaders in life sciences. The program focuses on innovative\, fundamental and translational research carried out in supportive and diverse academic and industrial environments\, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE \n\n\n\n\n\n\n\nOn-line event via Zoom \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\nPresenters: Prof. Jan Kihlberg & Assoc. prof. Vasanthanathan PoongavanamUppsala University\, Sweden \n\n\n\nAbstract:Most PROTACs which have a “druglike” oral bioavailability (>5%) are based on a CRBN E3-ligase ligand\, but a few VHL PROTACs also display >5% bioavailability. Use of 2D descriptors places oral drugs\, CRBN and VHL PROTACs in different parts of chemical space\, while the use of 3D descriptors indicates that the chemical spaces overlap. Use of 3D descriptors may therefore enhance the probability of discovering PROTACs with satisfactory oral bioavailability \n\n\n\nWe have studied CRBN and VHL PROTACs by NMR spectroscopy and MD simulations. These studies revealed that the propensity of the PROTACs to adopt folded and semi-folded conformations with low solvent – accessible 3D polar surface area correlated to higher cell permeability. The length\, chemical nature and flexibility of the linker was found to be essential for allowing intramolecular hydrogen bonds\, π–π interactions and van der Waals interactions to stabilize (semi)folded conformations for permeable PROTACs in a membrane-like environment. \n\n\n\nUse of MD simulations for prediction of the conformations and properties of PROTACs is time consuming. However\, classification models that were developed by machine learning using 2D descriptors allowed differentiation between VHL PROTACs that had high or low cell permeability. Such models can be integrated as effective filters to prioritize PROTACs for synthesis in the design process. Nevertheless\, certain challenges remain\, including the imbalanced nature of datasets\, and model interpretability. Addressing these limitations in future studies will be crucial for maximizing the full potential of machine learning in PROTAC design. \n\n\n\nBiographies:Jan Kihlberg holds a chair in Organic Chemistry at Uppsala University\, Sweden since 2013. His key research interests are to understand what properties convey cell permeability\, aqueous solubility and target binding to drugs such as PROTACs and macrocycles in the beyond rule of 5 space and to translate this knowledge into guidelines for design. He has published more than 200 peer–reviewed publications and book chapters. He establishing his independent research group at Lund University in 1991\, became full professor in Bioorganic Chemistry at Umeå University in 1996\, then moved to AstraZeneca R&D in Gothenburg in 2003 while maintaining a research group at Umeå University. At AstraZeneca Prof. Kihlberg held the role as Director\, Head of Medicinal Chemistry for seven years. \n\n\n\nVasanthanathan Poongavanam is a computational chemistry and AI expert at the DDD Platform\, SciLifeLab\, Uppsala University\, Sweden. His research focuses on applying computational chemistry and AI methodologies to accelerate drug discovery projects. He has authored more than 60 scientific publications\, including research articles\, reviews\, and book chapters.
URL:https://www.scilifelab.se/event/pulse-challenge-ml-ai-approaches-for-designing-proximity-inducing-small-molecules-protac-cell-permeability-and-bioavailability/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/02/Bild1-e1770905208628.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250219T150000
DTEND;TZID=Europe/Stockholm:20250219T163000
DTSTAMP:20260403T211440
CREATED:20250205T115115Z
LAST-MODIFIED:20250210T140957Z
UID:10001476-1739977200-1739982600@www.scilifelab.se
SUMMARY:PULSE Challenge: Properties and challenges with therapeutic oligonucleotides illustrated by hybridization-dependent off-target assessment
DESCRIPTION:This presentation will describe this workflow and discuss considerations for various ONT classes\, emphasizing the importance of ONT-specific factors such as chemistry\, delivery systems\, and tissue distribution in OffT evaluation. It will also cover strategies for experimental verification and risk assessment and discuss the potential of machine learning models to enhance OffT prediction. \n\n\n\nThe seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE\, that will train 48 future leaders in life sciences. The program focuses on innovative\, fundamental and translational research carried out in supportive and diverse academic and industrial environments\, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE \n\n\n\n\n\n\n\nOn-line event via Zoom \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\nPresenter: Dr Patrik Andersson\, PhDSenior Director\, RNA Therapeutics SafetyAstraZeneca\, Gothenburg\, Sweden \n\n\n\nAbstract:Hybridization-dependent off-target (OffT) effects\, occurring when oligonucleotides bind via Watson-Crick-Franklin hybridization to unintended RNA transcripts\, remain a critical safety concern for therapeutic oligonucleotides (ONTs). Despite the importance of OffT assessment of clinical trial ONT candidates\, formal guidelines were for many years lacking\, with only brief mentions in Japanese regulatory documents (2020) and FDA recommendations for HBV (hepatitis B virus) treatments (2022). A subcommittee of the Oligonucleotide Safety Working Group (OSWG)\, was formed to gather experiences and develop updated industry recommendations for assessing OffTs of ONTs. The proposed workflow encompasses five key steps: 1) OffT identification through in silico complementarity prediction and transcriptomics analysis\, 2) focus on cell types with relevant ONT activity\, 3) in vitro verification and margin assessment\, 4) risk assessment based on the OffT biological role\, and 5) management of unavoidable OffTs. \n\n\n\nThis presentation will describe this workflow and discuss considerations for various ONT classes\, emphasizing the importance of ONT-specific factors such as chemistry\, delivery systems\, and tissue distribution in OffT evaluation. It will also cover strategies for experimental verification and risk assessment and discuss the potential of machine learning models to enhance OffT prediction. \n\n\n\nBiography:Patrik joined AstraZeneca in Gothenburg\, Sweden 2004 as “Discovery Toxicologist”\, leading the safety work from target identification to candidate selection for numerous projects. From 2012\, he developed into an expert in the safety of nucleotide-based drugs and their delivery. This includes leading the non-clinical safety work internally at AstraZeneca and in collaborations with world leading companies in the fields of antisense oligonucleotides and therapeutic mRNA. Author of several peer reviewed primary and review papers and book chapters in the area of preclinical safety assessment of oligonucleotide therapeutics and active member in several cross-industry collaboration groups. Most recently active member of the EFPIA/PDEG and IQ/DruSafe oligo working groups and leading the OSWG subcommittee that resulted in a recently accepted paper on revised industry recommendations for off-target safety assessment (DOI: 10.1089/nat.2024.0072)
URL:https://www.scilifelab.se/event/pulse-challenge-properties-and-challenges-with-therapeutic-oligonucleotides-illustrated-by-hybridization-dependent-off-target-assessment/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/02/Bild1-e1770905208628.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20241112T120000
DTEND;TZID=Europe/Stockholm:20241112T170000
DTSTAMP:20260403T211440
CREATED:20240909T134717Z
LAST-MODIFIED:20241111T120146Z
UID:10001351-1731412800-1731430800@www.scilifelab.se
SUMMARY:Translational research as a boost for Swedish Life Science
DESCRIPTION:Learnings from the SciLifeLab model for drug discovery research\, ten years perspective \n\n\n\nThis symposium is part of the 10 year anniversary of the Drug Development and Discovery Platform at SciLifeLab. Translational research as a boost for Swedish Life Science: Learnings from the SciLifeLab model for drug discovery research\, ten years perspective \n\n\n\n \n\n\n\nregistration\n\n\n\nProgram \n\n\n\nProgram 10 års jubileum DDD_241107Download
URL:https://www.scilifelab.se/event/translational-research-as-a-boost-for-swedish-life-science/
LOCATION:Hotel Birger Jarl\, Birger Jarlsgatan 61\, Stockholm\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240815T110000
DTEND;TZID=Europe/Stockholm:20240815T114500
DTSTAMP:20260403T211440
CREATED:20240624T140804Z
LAST-MODIFIED:20240624T141010Z
UID:10001286-1723719600-1723722300@www.scilifelab.se
SUMMARY:Calls for new project support from  chemical biology and genome engineering platform and the drug discovery & development platform
DESCRIPTION:The Chemical Biology and Genome Engineering platform and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects support. \n\n\n\nThe Chemical Biology unit looks projects proposals including including assay development\, small molecule screening\, drug profiling\, and medicinal and computational chemistry.  For more information\, please visit www.cbcs.se. \n\n\n\nThe Chemical Biology and Genome Engineering platform are inviting project proposals aiming to explore compounds/drugs mechanism of action that harness the combined strengths of at least two platform units. If approved\, these projects will gain cost-effective access to CBGE’s cutting-edge technologies \n\n\n\nBoth the above welcome proposals in all areas of biology not only in human health. \n\n\n\nThe DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest\, including small molecules\, antibodies\, oligonucleotides and new modalities. \n\n\n\nSome users and projects are at the intersection between chemical biology and drug discoveryhttps://ki-se.zoom.us/j/61032835991 \n\n\n\nProgram: \n\n\n\n1. Presentation of CBGE offerings \n\n\n\n2. Presentation of the DDDp offerings \n\n\n\n3. Q/A
URL:https://www.scilifelab.se/event/calls-for-new-project-support-from-chemical-biology-and-genome-engineering-platform-and-the-drug-discovery-development-platform/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240515T150000
DTEND;TZID=Europe/Stockholm:20240515T154500
DTSTAMP:20260403T211440
CREATED:20240507T093945Z
LAST-MODIFIED:20240507T094614Z
UID:10001255-1715785200-1715787900@www.scilifelab.se
SUMMARY:Catalyzing Confidence: A Novel Strategy for Enhancing DEL Hit Validation in Drug Discovery
DESCRIPTION:Drug Discovery Seminars: Catalyzing Confidence: A Novel Strategy for Enhancing DEL Hit Validation in Drug Discovery \n\n\n\nPresenter: Dr Stefan Geschwindner\, PhD\, Director Biophysics\, AstraZeneca\, Mölndal\, Sweden \n\n\n\nHost: Pauliina Turunen\, Unit Target Protein Engineering (TPE)\, SciLifeLab DDD \n\n\n\n\n\n\n\nAbstract\n\n\n\nIn the realm of drug discovery\, validating hits derived from DNA-encoded library (DEL) screening is an indispensable step. This process necessitates the resynthesis and retesting of compounds to ascertain the consistency of observed activity while mitigating experimental artifacts. However\, the complexity arises from the fact that DNA barcodes in DEL libraries encode synthetic routes rather than chemical structures. This intricacy often leads to challenges in identifying genuine actives\, primarily due to incomplete chemical transformations during encoding\, resulting in low validation rates. \n\n\n\nIn response\, we will present a novel strategy for DEL hit validation. We will elucidate our approach\, which prominently features on-DNA compound resynthesis\, mirroring the methods employed during initial library synthesis. This seamlessly integrates with subsequent hit validation endeavors by using highly sensitivity surface-based biosensing in combination with a novel assay format. We will illustrate affinity correlations between on-DNA and off-DNA compounds\, offer insights into assay development\, and emphasize the utilization of enhanced sensitivity to allow us to detect low-abundancy on-DNA compounds. We will describe a systematic framework for DEL hit validation\, enhancing the identification of genuine binders with unwavering confidence and heightened sensitivity for drug discovery. \n\n\n\nSpeakers biography\n\n\n\nDr. Stefan Geschwindner is currently a Director at AstraZeneca R&D Gothenburg in Sweden where he is heading the Biophysics department within Discovery Sciences. He obtained his Ph.D. at the University of Frankfurt/Germany working predominantly with NMR to elucidate protein structures. After his Ph.D. he joined the Astra Structural Chemistry Laboratory with focus on protein engineering and characterization and helped to implement a variety of different biophysical methods and technologies in the early drug discovery process. Before moving into his current role\, he had different roles as Team leader in Protein Engineering and as Principal Scientist in Biophysics. His over 50 peer-reviewed publications are frequently cited leading to an h-index of 26.
URL:https://www.scilifelab.se/event/catalyzing-confidence-a-novel-strategy-for-enhancing-del-hit-validation-in-drug-discovery/
LOCATION:https://uu-se.zoom.us/j/65812174262
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2020/02/pills_600x200px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240212T140000
DTEND;TZID=Europe/Stockholm:20240212T153000
DTSTAMP:20260403T211440
CREATED:20240112T143939Z
LAST-MODIFIED:20240112T143942Z
UID:10001106-1707746400-1707751800@www.scilifelab.se
SUMMARY:The importance of target validation for successful academic drug discovery 
DESCRIPTION:Join us for an exciting webinar delving into the topic of target validation in academic drug discovery.  \n\n\n\nDiscover strategies for effective target validation from our experts. Register now for our joint webinar with Karolinska Institutet and SciLifeLab Drug Discovery & Development and secure your spot \n\n\n\nRead more
URL:https://www.scilifelab.se/event/the-importance-of-target-validation-for-successful-academic-drug-discovery/
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2023/02/DDD-text-logga.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20231107T130000
DTEND;TZID=Europe/Stockholm:20231107T140000
DTSTAMP:20260403T211440
CREATED:20231030T125153Z
LAST-MODIFIED:20231030T132952Z
UID:10001009-1699362000-1699365600@www.scilifelab.se
SUMMARY:Discovery of SARS-CoV-2 Main Protease inhibitors at the DDD platform
DESCRIPTION:Pandemic preparedness and the generation of SARS-CoV-2 inhibitors – A new exit from SciLifeLab Drug Discovery and Development platform \n\n\n\nDDD Exit Event 2023-11-07\, zoomcast 13.00 \n\n\n\n \n\n\n\nPresenters\n\n\n\nDr. Ulf Ribacke. Dept. of Microbiology\, Tumor and Cell Biology\, Karolinska InstitutetTel: +46 70 497 5196\, Email: ulf.ribacke@ki.se \n\n\n\nProf. Jens Carlsson\, Dept. of Cell and Molecular Biology\, Uppsala UniversityTel: +46 72 227 7976\, Email: jens.carlsson@icm.uu.se \n\n\n\nAbstract\n\n\n\nSciLifeLab has been commissioned by the government to build laboratory capacity to assist in future pandemics through research and competence and technology development. Hear more about the SciLifeLab Pandemic Laboratory Preparedness program from Ulf Ribacke\, (SciLifeLab and Karolinska Institutet) and groundbreaking research performed by researchers at Uppsala University that led to discovery of potent main protease SARS-CoV-2 inhibitors. \n\n\n\nJens Carlsson\, Helena Danielson\, Anja Sandström and Lindon Moodie have recently signed an agreement for international partnering of a project focusing on development of drugs for treatment of COVID-19 (DP_JC_188). \n\n\n\nThe project was funded by the National COVID-19 Research Program initiated by the Knut and Alice Wallenberg Foundation. Hit compounds identified by virtual screening were published in 2022 by Luttens et al. (https://doi.org/10.1021/jacs.1c08402). Hit-to-lead generation was then performed together with the Drug Discovery and Development Platform in the DP_JC_188 project. Lead optimization and preclinical development of assets are now supported by an international pharmaceutical company. \n\n\n\nShort speakers biography:\n\n\n\nUlf Ribacke: Ulf is scientific co-director of the SciLifeLab Pandemic Laboratory Preparedness program and heads two research labs located at Karolinska Institutet and Uppsala University\, both dedicated to resolve how malaria parasites adapt to evade cellular stress with the ultimate goal to identify targets for new interventions. \n\n\n\nJens Carlsson: Jens is a Professor of Computational Biochemistry at Uppsala University\, where his group uses computational models to understand protein function at the molecular level and develops strategies for drug discovery.For more information\, visit http://www.carlssonlab.org/. \n\n\n\nUlf RibackeKarolinska InstitutetScientific Lead – Pandemic Laboratory Preparedness at SciLifeLabulf.ribacke@ki.se\n\n\n\nJens CarlssonUppsala Universityjens.carlsson@icm.uu.se
URL:https://www.scilifelab.se/event/discovery-of-sars-cov2-mpro-inhibitors-at-the-ddd-platform/
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230816T100000
DTEND;TZID=Europe/Stockholm:20230816T104500
DTSTAMP:20260403T211440
CREATED:20230621T114415Z
LAST-MODIFIED:20230815T130146Z
UID:10000919-1692180000-1692182700@www.scilifelab.se
SUMMARY:Project support in chemical biology and drug discovery
DESCRIPTION:The chemical biology unit (CBCS) and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects. \n\n\n\nCBCS is looking for projects in Chemical Biology which includes assay development for small molecule screening and profiling\, as well as enabling chemistry. For more information\, please visit www.cbcs.se. \n\n\n\nThe DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest\, including small molecules\, antibodies\, oligonucleotides and new modalities. \n\n\n\nSome users and projects are at the intersection between chemical biology and drug discovery. This webinar aims to guide users to the call that best suits the needs of their project. \n\n\n\nregister here to receive link\n\n\n\nDocumentation\n\n\n\nDDD Call for Projects \n\n\n\nCBCS Large Projects Call 2023 \n\n\n\nWebinar Slides CBCS \n\n\n\nWebinar Slides DDD
URL:https://www.scilifelab.se/event/project-support-in-chemical-biology-and-drug-discovery-2/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230628T110000
DTEND;TZID=Europe/Stockholm:20230628T120000
DTSTAMP:20260403T211440
CREATED:20230616T074651Z
LAST-MODIFIED:20230616T074652Z
UID:10000917-1687950000-1687953600@www.scilifelab.se
SUMMARY:Call for new drug discovery pilot projects at SciLifeLab DDD with special emphasis on biologics and antibiotics
DESCRIPTION:The DDD platform at SciLifeLab supports academic drug discovery project with expertise and technical capabilities. We have\, for example\, platforms to develop small molecule drugs\, therapeutic antibodies\, oligonucleotide therapeutics\, proximity-inducing agents such as bispecific antibodies and PROTACs.  \n\n\n\nIn this call\, the Drug Discovery and Development Platform (DDD) at SciLifeLab is looking for new pilot project proposals for drug discovery. All therapeutic modalities outlined above are of interest. Of special interest are new project ideas for (multispecific) biologics\, and in collaboration with ENABLE2 https://www.ilk.uu.se/enable2/\, small molecule projects for discovery of new antibiotics. \n\n\n\nNote that small projects for selections in phage display libraries for antibodies\, selections in DNA encoded chemical libraries for small molecules or limited screening for antisense or siRNA molecules can be considered.  \n\n\n\nA description of new modalities in drug discovery research can be found here: https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00582 \n\n\n\nIf you have questions about the call please contact DDD by email (dddprojectproposal@scilifelab.se). This call is open for scientists with a doctoral degree at a Swedish university or higher institution. English should be used when filling out this application. You are responsible for ensuring that the application is complete. Incomplete applications will not be processed. \n\n\n\nProgram\n\n\n\n11.00 Introduction to Anubis call for DDD pilot-projects\, Per Arvidsson \n\n\n\n11.05 Oligonucleotide therapeutics through OligoNova HUB at DDD\, Pär Matsson \n\n\n\n11.30 Questions & Answers \n\n\n\n11.45 End with a video about collaboration with SciLifeLab DDD featuring Marika Nestor\, Uppsala University \n\n\n\n \n\n\n\nWelcome!\n\n\n\nRegistration\n\n\n\nMore About the call\n\n\n\nLink to Online Event
URL:https://www.scilifelab.se/event/call-for-new-drug-discovery-pilot-projects-at-scilifelab-ddd-with-special-emphasis-on-biologics-and-antibiotics/
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230320T110000
DTEND;TZID=Europe/Stockholm:20230320T170000
DTSTAMP:20260403T211440
CREATED:20230221T103002Z
LAST-MODIFIED:20230315T111656Z
UID:10000816-1679310000-1679331600@www.scilifelab.se
SUMMARY:Kinase Drug Discovery - Strategies for Success
DESCRIPTION:A half day dedicated to kinases in drug discovery organized by SciLifeLab DDD in collaboration with AstraZeneca.  \n\n\n\nKinases continue to attract much attention in drug discovery. Since the first compounds were launched in 2001 the learning curve of how to tackle different challenges has been steep. At the symposium we hope to give a broad overview where the field stands today and the different approaches one can take in drug discovery when interacting with kinases.  \n\n\n\nIn the late afternoon we will dive deeper into the details of data generation and data interpretation to learn and discuss different techniques that can be applied to increase the chance for success. \n\n\n\nThe meeting is believed to be valuable for researchers in the area of drug discovery like medicinal chemists\, structural biologists\, pharmacologists\, protein scientists\, toxicologists etc.  \n\n\n\nThis is a hybrid event. Registration for the conference on site is binding and last day for on site participation is March 14th. \n\n\n\nRead more\n\n\n\nRegister\n\n\n\n\n\n\n\nProgram
URL:https://www.scilifelab.se/event/kinase-drug-discovery-strategies-for-success/
LOCATION:Inghesalen\, Tomtebodavägen 18a\,\, Solna\, 171 65 171 65\, Sweden
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2023/02/Bild-2a-1-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230314T083000
DTEND;TZID=Europe/Stockholm:20230314T113000
DTSTAMP:20260403T211440
CREATED:20230207T121841Z
LAST-MODIFIED:20230213T154000Z
UID:10000805-1678782600-1678793400@www.scilifelab.se
SUMMARY:Electro- and Photoredox Chemistry – with a Practical touch
DESCRIPTION:At these two seminars you will hear about the two techniques of electrosynthesis and photoredoxchemistry\, used more and more today by organic chemists. We will get some background information to the techniques and examples from how it is used in Helena’s and Markus’ labs. After the seminars we hope that you better understand when the techniques are best used and that you also get practical examples on how to get started. \n\n\n\nWe hope to discuss what can be future developments in field. \n\n\n\nAt the venue we will bring examples of equipment that can be used. \n\n\n\nWe meet up in the entrance at Gamma 2 for coffee and walk up together (be there in time\, so we can let you in). To reserve a sandwich please register before March 7th to ylva.gravenfors@scilifelab.se \n\n\n\n \n\n\n\nWe look forward to seeing you there! \n\n\n\nPresenter\n\n\n\nDr Helena Lundberg\, Ass. Professor at KTH \n\n\n\nhellundb@kth.se \n\n\n\nDr Markus Kärkäs\, Assoc. Professor at KTH \n\n\n\nkarkas@kth.se \n\n\n\nSpeakers‘ biographies \n\n\n\nHelena is Assistant Professor in organic chemistry since 2021 and has been a principal investigator at KTH Royal Institute of Technology since early 2019. Helena’s research interests are centered around catalysis and reductive electrosynthesis.   \n\n\n\nMarkus is Associate Professor in organic chemistry and a principal investigator at KTH Royal Institute of Technology since August 2018. His research interests include photoredox catalysis\, organic electrosynthesis\, and artificial photosynthesis. \n\n\n\nThe Drug Discovery and Development Platform\n\n\n\nHit2Lead – Read more
URL:https://www.scilifelab.se/event/electro-and-photoredox-chemistry-with-a-practical-touch/
LOCATION:Gamma 7 Lunchroom\, Tomtebodavägen 23A\, Solna\, 17121
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230124T100000
DTEND;TZID=Europe/Stockholm:20230124T104500
DTSTAMP:20260403T211440
CREATED:20230110T160227Z
LAST-MODIFIED:20230124T132100Z
UID:10000783-1674554400-1674557100@www.scilifelab.se
SUMMARY:Project support in chemical biology and drug discovery
DESCRIPTION:The chemical biology unit (CBCS) and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects. \n\n\n\nCBCS is looking for projects in Chemical Biology which includes assay development for small molecule screening and profiling\, as well as enabling chemistry. For more information\, please visit www.cbcs.se. \n\n\n\nThe DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest\, including small molecules\, antibodies\, oligonucleotides and new modalities. \n\n\n\nSome users and projects are at the intersection between chemical biology and drug discovery.This webinar aims to guide users to the call that best suits the needs of their project. \n\n\n\nDocumentation\n\n\n\nDDD Call for Projects\n\n\n\nWebinar Slides CBCS\n\n\n\nWebinar Slides PPP
URL:https://www.scilifelab.se/event/project-support-in-chemical-biology-and-drug-discovery/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2022/04/Pawel_DDD_WP.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230119T080000
DTEND;TZID=Europe/Stockholm:20230119T170000
DTSTAMP:20260403T211440
CREATED:20221209T130532Z
LAST-MODIFIED:20221213T124743Z
UID:10000746-1674115200-1674147600@www.scilifelab.se
SUMMARY:Uppsala University Pharmaceutical Profiling in Drug Discovery and Development Symposium
DESCRIPTION:Every year\, the Drug Delivery group at the Department of Pharmacy (headed by Prof. Per Artursson\, Prof. Christel Bergström and Dr. Pawel Baranczewski) organizes a one-day symposium on pharmaceutical profiling. On January 19th\, 2023\, the 12th Uppsala University Pharmaceutical Profiling in Drug Discovery and Development Symposium will be arranged.  \n\n\n\nregistration\n\n\n\nThis twelfth edition of the symposium will focus on new modalities with respect to their development and formulation to overcome biological barriers and achieve targeted therapies. Past symposia have been highly attended by faculty and students at Uppsala University and other Swedish and international universities\, as well as by researchers from the local biotech and pharma industry and from regulatory agencies.  \n\n\n\nPrevious keynote speakers included among others Prof. Langer (MIT)\, Prof. Alonso (USC CIMUS Research Institute)\, Prof. Porter (Monash University)\, Prof. Leroux (ETH Zürich) and Dr. Hochman (Merck). The symposia provide excellent opportunities for academia-industry networking and for scientific discussions on current research at our platform for drug optimization and pharmaceutical profiling as well as in the Drug Delivery research group at the Department of Pharmacy.  \n\n\n\nThis year’s confirmed speakers and the titles of their talks:  \n\n\n\n\nProf. Olivia Merkel (Ludwig-Maximilians-Universität München\, Germany): Treatment of lung diseases via siRNA inhalation delivery \n\n\n\nProf. Paola Luciani (University of Bern\, Switzerland): Targeting fibrosis in multiple organs via lipid-based drug delivery systems \n\n\n\nProf. Ola Söderberg (Uppsala University\, Sweden): Development of novel molecular biology tools for medical research \n\n\n\nAssist. Prof. Daniel Fürth (Uppsala University\, Sweden): A chemoselective in vivo sequencing chemistry \n\n\n\nProf. Yvonne Perrie (University of Strathclyde\, Scotland): Formulation strategies for the delivery of mRNA vaccines \n\n\n\nProf. My Hedhammar (KTH Royal Institute of Technology/Spiber Technologies AB\, Sweden): FN-silk membrane as mimic of basement membrane in tissue barrier models \n\n\n\nAssoc. Prof. Daniel Espes (Uppsala University\, Sweden): Novel imaging techniques and drugs for targeting human pancreatic islets \n\n\n\nProf. Per I Arvidsson (Karolinska Institutet\, Sweden): Explorations and innovations at the academia-industry interface – tales from the SciLifeLab DDD infrastructure \n\n\n\nProf. Jens Carlsson (Uppsala University\, Sweden): Antiviral drug discovery by virtual screening of ultra-large chemical libraries \n\n\n\n\nThere will also be a panel discussion about “Impact of European drug delivery science”\, led by Dr. Björn Arvidsson. \n\n\n\nOrganizers: \n\n\n\n\nDrug Delivery group\, Uppsala University\n\n\n\nSciLifeLab\n\n\n\nUDOPP
URL:https://www.scilifelab.se/event/uppsala-university-pharmaceutical-profiling-in-drug-discovery-and-development-symposium/
LOCATION:Humanities Theater\, Engelska parken\, Uppsala\, 75238\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230111T110000
DTEND;TZID=Europe/Stockholm:20230111T114500
DTSTAMP:20260403T211440
CREATED:20221220T095206Z
LAST-MODIFIED:20230109T155739Z
UID:10000754-1673434800-1673437500@www.scilifelab.se
SUMMARY:Call for new drug discovery pilot projects at SciLifeLab DDD with special emphasis on new modalities and antibiotics
DESCRIPTION:Program\n\n\n\n\nInformation of new DDD call in Anubis – Per Arvidsson\n\n\n\n”Antibiotic research through DDD and Enable2” – Anders Karlén\n\n\n\n”New modalities as therapies of the future” – Per Arvidsson\n\n\n\n\nIn this call\, the Drug Discovery and Development Platform (DDD) at SciLifeLab is looking for new pilot project proposals for drug discovery. All therapeutic modalities are of interest. Of special interest are new project ideas for new modalities including therapeutic oligonucleotides\, and in collaboration with ENABLE2 https://www.ilk.uu.se/enable2/\, projects for discovery of new antibiotics. \n\n\n\nNote that shorter projects for selections in phage display libraries for antibodies and in DNA encoded chemical libraries for small molecules can be considered.A description of new modalities in drug discovery research can be found here: https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00582 \n\n\n\nProgram\n\n\n\n11.00 Introduction to Anubis call for DDD pilot-projects\, Kristian Sandberg \n\n\n\n11.05 Antibiotic drug discovery through ENABLE2 and DDD\, Anders Karlén \n\n\n\n11.15 Oligonucleotide therapeutics through OligoNova HUB at DDD\, Pär Matsson \n\n\n\n11.25 New therapeutic modalities and selection in enormous antibody and small molecule libraries\, Per Arvidsson \n\n\n\n11.40 Questions & Answers\, Moderated by Kristian Sandberg \n\n\n\nIf you have questions about the call please contact DDD by email (dddprojectproposal@scilifelab.se). This call is open for scientists with a doctoral degree at a Swedish university or higher institution. English should be used when filling out this application. You are responsible for ensuring that the application is complete. Incomplete applications will not be processed. \n\n\n\nMore about the call\n\n\n\nRegistration to the Event
URL:https://www.scilifelab.se/event/call-for-new-drug-discovery-pilot-projects-at-scilifelab-ddd-with-special-emphasis-on-new-modalities-and-antibiotics/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220815T113000
DTEND;TZID=Europe/Stockholm:20220815T121500
DTSTAMP:20260403T211440
CREATED:20220615T132143Z
LAST-MODIFIED:20220622T114102Z
UID:10000625-1660563000-1660565700@www.scilifelab.se
SUMMARY:Calls for new project support in chemical biology and drug discovery
DESCRIPTION:The chemical biology unit (CBCS) and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects. \n\n\n\nCBCS is looking for projects in Chemical Biology which includes assay development for small molecule screening and profiling\, as well as enabling chemistry. For more information\, please visit www.cbcs.se. \n\n\n\nThe DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest\, including small molecules\, antibodies\, oligonucleotides and new modalities. \n\n\n\nSome users and projects are at the intersection between chemical biology and drug discovery.This webinar aims to guide users to the call that best suits the needs of their project. \n\n\n\nRegistration
URL:https://www.scilifelab.se/event/calls-for-new-project-support-in-chemical-biology-and-drug-discovery/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220617T113000
DTEND;TZID=Europe/Stockholm:20220617T121500
DTSTAMP:20260403T211440
CREATED:20220608T073241Z
LAST-MODIFIED:20220608T114734Z
UID:10000623-1655465400-1655468100@www.scilifelab.se
SUMMARY:Call for new drug discovery projects - New SciLifeLab Capability for DNA encoded chemical libraries
DESCRIPTION:Call for new drug discovery projects to SciLifeLab DDD for the fall 2022 and introduction of a SciLifeLab capability for DNA encoded chemical libraries \n\n\n\nThe Drug Discovery and Development platform at SciLifeLab (DDD) opens for new project applications for the fall 2022. New proposals will be accepted for all therapeutic modalities that are currently part of the DDD offer\, i.e. small molecules\, biologics (antibodies\, proteins\, etc)\, or therapeutic oligonucleotides.  \n\n\n\nIn this presentation\, we will zoom in on selection of small molecule protein binders from enormously large DNA encoded chemical libraries containing >5 Billion physical small molecules. \n\n\n\nMost welcome! \n\n\n\nRegister to receive zoom link\n\n\n\nCall application form
URL:https://www.scilifelab.se/event/call-for-new-drug-discovery-projects-new-scilifelab-capability-for-dna-encoded-chemical-libraries/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220525T130000
DTEND;TZID=Europe/Stockholm:20220525T140000
DTSTAMP:20260403T211440
CREATED:20220507T134201Z
LAST-MODIFIED:20220510T114934Z
UID:10000603-1653483600-1653487200@www.scilifelab.se
SUMMARY:A novel\, antibody-based radiopharmaceutical for advanced thyroid cancer
DESCRIPTION:Presenter: Dr Marika Nestor\, Department of Immunology\, genetics and pathology\, Uppsala University\, Sweden \n\n\n\nMolecular radiotherapy is increasingly becoming a powerhouse in the field of cancer- and radiation therapy. By targeting a structure that is abundant on tumor cells but scarce in healthy tissues\, a cancer-targeting molecule labeled with a therapeutic radionuclide can mediate the delivery of radioactivity specifically to cancer cells. This creates a targeted\, localized form of radiotherapy that combines the advantages of systemic therapy with therapeutically effective radiation. \n\n\n\nIn a collaboration with the Drug Discovery & Development platform at Science for Life Laboratory\, we have developed an antibody-based radiopharmaceutical for molecular radiotherapy of advanced thyroid carcinoma. The project spans over the whole early development chain; from preclinical innovation in the lab\, dosimetry and proof-of-concept in animal models\, to upscaled production and preparations for first-in-man studies. \n\n\n\nDr Nestor in her presentation will discuss the process from innovation to implementation of the project\, both from a research and a commercialization perspective. \n\n\n\nsign up here\n\n\n\nMarika Nestor leads a translational research group at the Department of Immunology\, Genetics and Pathology\, Uppsala University. Her research group focuses on radionuclide targeting and radiosensitization of cancer cells. She obtained her PhD at Uppsala University in 2006\, and became an Associate Professor in 2012. In 2013 she was awarded the Göran Gustafsson prize for young scientists\, in 2016 the Junior Investigator Award from the Swedish Cancer Society\, and in 2020 the Senior Investigator Award. In 2019\, she was awarded a grant from Sweden’s innovation agency VINNOVA to facilitate clinical translation of her findings\, as well as an Attractive Innovation Award by UU Innovation.
URL:https://www.scilifelab.se/event/a-novel-antibody-based-radiopharmaceutical-for-advanced-thyroid-cancer/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220426T093000
DTEND;TZID=Europe/Stockholm:20220426T120000
DTSTAMP:20260403T211440
CREATED:20220411T114853Z
LAST-MODIFIED:20220411T115121Z
UID:10000581-1650965400-1650974400@www.scilifelab.se
SUMMARY:New developments in upstream bioprocessing technologies seminar
DESCRIPTION:Presentation och demonstration av nya single use bioreactors (SUB) för mammalieceller.  \n\n\n\nregister to attend\n\n\n\nProgram:  \n\n\n\n9:30-10:15 Matthijs Neimeijer\, Cultivating red blood cells in singe-use bioreactors \n\n\n\n10:15-10:45 Fika och demonstration \n\n\n\n10:45-11:30 Michel Kensler\, Comparisons in scale up and down scale \n\n\n\n11:30-12:00 Questions
URL:https://www.scilifelab.se/event/new-developments-in-upstream-bioprocessing-technologies-seminar/
LOCATION:Air&Fire\, SciLifeLab Stockholm\, Tomtebodavägen 23A\, Solna\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220404T140000
DTEND;TZID=Europe/Stockholm:20220404T150000
DTSTAMP:20260403T211440
CREATED:20220325T125600Z
LAST-MODIFIED:20220325T143719Z
UID:10000569-1649080800-1649084400@www.scilifelab.se
SUMMARY:Information Meeting: Call for therapeutic oligonucleotide projects
DESCRIPTION:This digital information meeting will be held April 4\, 2022 at 14.00–15.00. At this meeting\, there will be a presentation of the call and you as an applicant will have the opportunity to ask questions about the call and the application process. \n\n\n\nregister here to receive zoom link\n\n\n\nApply in the call here\n\n\n\nThe mission of the Drug Discovery and Development Platform at SciLifeLab is to support researchers in developing new drugs\, transforming academic ideas into new treatments. To this end\, the DDD platform provides state-of-the-art drug discovery technologies to scientists across the country. Therapeutic oligonucleotides are a recent addition to the DDD platform’s capacity\, complementing the previous focus on small molecule and protein drugs. Oligonucleotide drugs have different modes of action\, and a potentially faster development compared to other drug types. Therapeutic oligonucleotide development is supported by the OligoNova Hub\, based in Gothenburg and part of SciLifeLab’s DDD platform. \n\n\n\nIn this call\, we are looking for project ideas for new therapeutic oligonucleotides that can be developed at DDD and OligoNova Hub. Approved project ideas will be developed in close collaboration between the academic laboratory and drug development experts at DDD and OligoNova Hub. The costs of the projects will mainly be covered by OligoNova\, but academic partners will be expected to contribute by paying for reagent costs. \n\n\n\nThe call is open for scientists with a doctoral degree at a Swedish university or higher institution. English should be used when filling out this application. You are responsible for ensuring that the application is complete. Incomplete applications will not be processed. Attach only material that we explicitly request. SciLifeLab DDD/OligoNova will not accept additional information after the closing date for applications\, except for information we ourselves explicitly request. Applications are reviewed by a review committee with international representation. \n\n\n\nCall Announcement FlyerDownload\n\n\n\nThe call is open March 28\, 2022 to May 13\, 2022.
URL:https://www.scilifelab.se/event/information-meeting-call-for-therapeutic-oligonucleotide-projects/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220127T084500
DTEND;TZID=Europe/Stockholm:20220127T170000
DTSTAMP:20260403T211440
CREATED:20211130T143050Z
LAST-MODIFIED:20211130T160953Z
UID:10000492-1643273100-1643302800@www.scilifelab.se
SUMMARY:11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development
DESCRIPTION:Uppsala University’s Department of Pharmacy hosts the 11th Pharmaceutical Profiling meeting on Thursday\, January 27\, 2022\, at The Humanities Theatre\, English Park Campus\, Uppsala. \n\n\n\nJanuary 27\, 2022The Humanities Theatre\, English Park Campus\, UppsalaConfirmed speakers \n\n\n\nKathryn A. Whitehead (Carnegie Mellon University\, US)Ola Engkvist (AstraZeneca\, Sweden)Carolina Wählby (Uppsala University\, Sweden)Samir EL Andaloussi (Karolinska Institutet\, Sweden)Ola Spjuth (Uppsala University\, Sweden)Pär Matsson (University of Gothenburg\, Sweden)Annabelle Biscans (AstraZeneca\, Sweden)\n\n\n\nWe highly encourage all participants to bring a scientific poster.
URL:https://www.scilifelab.se/event/11th-symposium-on-pharmaceutical-profiling-in-drug-discovery-and-development/
LOCATION:Humanities Theater\, Engelska parken\, Uppsala\, 75238\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211208T140000
DTEND;TZID=Europe/Stockholm:20211208T150000
DTSTAMP:20260403T211440
CREATED:20211124T131507Z
LAST-MODIFIED:20211206T105940Z
UID:10000491-1638972000-1638975600@www.scilifelab.se
SUMMARY:SciLifeLab Drug Discovery Seminar & DDD Exit event: Thomas Helleday
DESCRIPTION:Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress\n\n\n\n\n\n\n\nProfessor Thomas Helleday\, Karolinska Institutet \n\n\n\nSciLifeLab Drug Discovery Seminars\, hosted by the DDD platform\, is a series of educational lectures about recent developments\, technologies\, and trends in drug discovery and development that aims to enlighten\, and spark a discussion\, within the Swedish drug discovery community. \n\n\n\nAbstract \n\n\n\nThe folate metabolism enzyme MTHFD2 is consistently overexpressed in cancer but its roles are not fully characterized and current candidate inhibitors have limited potency for clinical development. Here we demonstrate a role for MTHFD2 in DNA replication and genomic stability in cancer cells\, and present optimised potent and selective nanomolar MTHFD2 inhibitors (MTHFD2i); protein co-crystal structures demonstrated binding to the active site of MTHFD2 and target engagement and that works in vitro and in vivo. \n\n\n\nThe results demonstrate a functional link between MTHFD2-dependent cancer metabolism and replication stress that can be exploited therapeutically with this new class of inhibitors. The work\, done in collaboration with the SciLifeLab DDD platform\, is accepted in the journal Nature Cancer and is the base for the creation of a new company: One-carbon therapeutics AB.  \n\n\n\nregistration
URL:https://www.scilifelab.se/event/scilifelab-drug-discovery-seminar-ddd-exit-event/
LOCATION:Air&Fire\, SciLifeLab Stockholm\, Tomtebodavägen 23A\, Solna\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211112T140000
DTEND;TZID=Europe/Stockholm:20211112T150000
DTSTAMP:20260403T211440
CREATED:20211014T151650Z
LAST-MODIFIED:20211020T131013Z
UID:10000467-1636725600-1636729200@www.scilifelab.se
SUMMARY:[Drug Discovery Seminar] PROTAC Degraders: From Fundamental Chemical Biology to Translation and Entrepreneurship
DESCRIPTION:SciLifeLab Drug Discovery Seminars\, hosted by the DDD platform\, is a series of educational lectures about recent developments\, technologies\, and trends in drug discovery and development that aims to enlighten\, and spark a discussion\, within the Swedish drug discovery community. \n\n\n\nAlessio Ciulli\n\n\n\nProfessor of Chemical Structural Biology \n\n\n\nCentre for Targeted Protein Degradation\, School of Life Sciences\, Division of Biological Chemistry and Drug Discovery\, University of Dundee \n\n\n\n \n\n\n\nAbstract\n\n\n\nProteolysis-targeting chimeras (PROTACs) are a new class of chemical tools and drugs that target disease-causing proteins for degradation. They are designed to harness the cell’s natural disposal system (the ubiquitin-proteasome) to specifically remove proteins. A PROTAC is a two-headed (i.e. bifunctional) molecule where one end binds an enzyme (an E3 ubiquitin ligase) and the other binds the target protein\, bringing the two proteins into close proximity as a ternary complex. The ligase is then able to label the target protein for ubiquitination and so degradation by the cell’s disposal system. Whereas conventional drugs only inhibit disease proteins by binding and locking up their most important functional parts for the duration of the drug’s action\, PROTACs can bind at any positions and rapidly cause the disease protein’s permanent and long-lasting destruction. Due to this revolutionary mode of action\, PROTACs can attack targets previously thought ‘undruggable’.  \n\n\n\nIn my lecture\, I will outline some key discoveries from my laboratory that have advanced the chemical structural biology of PROTACs\, and are providing fundamental insights into our understanding of their molecular recognition\, mechanism of action and drug design. I will also offer insights from our efforts to translate this fundamental science into molecular therapeutics to benefit patients\, via both partnerships with big pharma and formation of company spin-outs. Finally I will highlight the vision and mission of our recently announced new Centre for Targeted Protein Degradation at Dundee. \n\n\n\nShort Bio\n\n\n\n\n\n\n\nAlessio Ciulli holds the Personal Chair of Chemical Structural Biology at the School of Life Sciences\, University of Dundee. He is also the Director of the newly announced Dundee’s Centre for Targeted Protein Degradation (CeTPD). Dr Ciulli’s laboratory has made important contributions to selective chemical intervention on protein-protein interactions targets and to the development of proteolysis-targeting chimeric molecules (PROTACs) as a viable strategy for targeted protein degradation. Amongst his most significant discoveries are the fragment-based design of ligands for the E3 ligase von Hippel-Lindau (VHL)\, and their use to design one of the first VHL-based PROTACs: the BET degrader MZ1. Dr Ciulli’s Lab later illuminated fundamental insights into PROTACs’ mechanism of action\, solving the first crystal structure of a PROTAC ternary complex. Dr. Ciulli is the scientific founder of Amphista therapeutics\, a company that develops new protein degradation platforms. Before joining Dundee\, Dr Ciulli was a group leader at the University of Cambridge\, where he previously earned his PhD degree. Amongst his honours are the EFMC Prize for Young Medicinal Chemist in Academia\, the RSC Capps Green Zomaya Award in medicinal computational chemistry\, and election as Fellow of the Royal Society of Chemistry. \n\n\n\n \n\n\n\nRegistration
URL:https://www.scilifelab.se/event/drug-discovery-seminar-protac-degraders-from-fundamental-chemical-biology-to-translation-and-entrepreneurship/
LOCATION:Navet\, SciLifeLab Uppsala\, SciLifeLab Uppsala\, BMC C11\, Husargatan 3\, Uppsala\, 75237\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211110T140000
DTEND;TZID=Europe/Stockholm:20211110T150000
DTSTAMP:20260403T211440
CREATED:20211014T151000Z
LAST-MODIFIED:20211020T130718Z
UID:10000466-1636552800-1636556400@www.scilifelab.se
SUMMARY:[Drug Discovery Seminar] How protein degradation led to faculty entrepreneurship at Yale: A personal Perspective
DESCRIPTION:SciLifeLab Drug Discovery Seminars\, hosted by the DDD platform\, is a series of educational lectures about recent developments\, technologies\, and trends in drug discovery and development that aims to enlighten\, and spark a discussion\, within the Swedish drug discovery community. \n\n\n\nCraig Crews\n\n\n\n\n\n\n\n \n\n\n\nJohn C. Malone Professor of Molecular\, Cellular\, and Developmental Biology and Professor of Chemistry\, of Pharmacology\, and of Management; Executive Dirictor\, Yale Center for Molecular Discovery\, Yale University \n\n\n\nAbstract \n\n\n\nProf. Crews is the 2021 recipient of the Scheele prize from the Swedish Pharmaceutical Society for his seminal work on protein degradation. In this talk Prof. Crews will discuss his efforts to translate research from his lab into new biopharma ventures.  To date\, these entrepreneurial  efforts have resulted in a FDA approved drug (Kyprolis) and a new therapeutic modality (PROTACs).  While each of his four companies has been launched based on different science\, they have all followed a similar business model and Prof. Crews will discuss efforts at Yale to ’systematize’ faculty entrepreneurism via a core ‘biotech accelerator’ facility. \n\n\n\nregistration\n\n\n\nBiography \n\n\n\nCrews is the John C. Malone Professor of Molecular\, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He graduated from the U.Virginia with a B.A. in Chemistry and received his Ph.D. from Harvard University in Biochemistry. Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995\, his laboratory has pioneered the use of small molecules to control intracellular protein levels.  \n\n\n\nIn 2003\, he co-founded Proteolix\, Inc.\, whose proteasome inhibitor\, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Since Proteolix’s purchase by Onyx Pharmaceuticals in 2009\, Dr. Crews has focused on a new drug development technology\, which served as the founding intellectual property for his latest New Haven-based biotech venture\, Arvinas\, Inc.  \n\n\n\nCurrently\, Dr. Crews serves on several editorial boards and was Editor of Cell Chemical Biology (2008-2018). In addition\, he has received numerous awards and honors\, including the 2013 CURE Entrepreneur of the Year Award\, 2014 Ehrlich Award for Medicinal Chemistry\, 2015 Yale Cancer Center Translational Research Prize\, a NIH R35 Outstanding Investigator Award (2015)\, the AACR Award for Chemistry in Cancer Research (2017)\, Khorana Prize from the Royal Society of Chemistry (2018)\, Pierre Fabre Award for Therapeutic Innovation (2018)\, the Pharmacia-ASPET Award for Experimental Therapeutics (2019)\, the Heinrich Wieland Prize (2020) and the Scheele Prize (2021). In 2019\, he was named an American Cancer Society Professor.
URL:https://www.scilifelab.se/event/drug-discovery-seminar-faculty-entrepreneurship-at-yale-a-personal-perspective/
LOCATION:Air&Fire\, SciLifeLab Stockholm\, Tomtebodavägen 23A\, Solna\, Sweden
CATEGORIES:Event
END:VEVENT
END:VCALENDAR